ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Small cell lung cancer (SCLC) is aggressive with poor outcomes.
• Immune checkpoint inhibitors (ICIs) benefit SCLC but resistance develops.
• Mechanisms of immune evasion in SCLC require further investigation.

Purpose of the Study:

• To investigate mechanisms of immune evasion in SCLC.
• To identify therapeutic targets for overcoming SCLC immune resistance.

Main Methods:

• High-dimensional profiling of human and murine SCLC specimens.
• Analysis of MHC-I expression in primary versus metastatic samples.
• Mass spectrometry and phospho-tyrosine kinase analyses to identify signaling pathways.
• Genetic and pharmacologic blockade of ERBB2 in murine SCLC models.
• Combination therapy with ERBB2 inhibition and anti-PD-1.

Main Results:

• MHC-I loss is observed in SCLC metastases, correlating with immune evasion.
• Silencing MHC-I promotes SCLC metastasis and reduces immune infiltration in mice.
• ERBB2 signaling suppresses MHC-I expression and drives immune-modulatory transcripts.
• ERBB2 blockade induces MHC-I via STING and prevents immune evasion in murine SCLC.
• Combination of ERBB2 inhibition and anti-PD-1 demonstrates synergistic efficacy in preclinical SCLC models.

Conclusions:

• MHC-I loss is a key immune evasion mechanism in SCLC, driven by ERBB2.
• Targeting ERBB2 signaling can restore MHC-I expression and enhance anti-tumor immunity.
• Combined ERBB2 inhibition and anti-PD-1 therapy offers a promising strategy for SCLC treatment.